Literature DB >> 9155042

Resistance of ovarian teratocarcinoma cell spheroids to complement-mediated lysis.

L Bjørge1, S Junnikkala, E K Kristoffersen, J Hakulinen, R Matre, S Meri.   

Abstract

We have shown previously that it is possible to target complement-mediated killing against cultured ovarian tumour cells in vitro. As malignant ovarian cells usually grow in solid nodules in vivo, we have in the present study examined the effectiveness of complement killing against ovarian teratocarcinoma cells (PA-1) growing in three-dimensional tumour microspheroids (TMSs). Our study shows that PA-1 cells growing in TMSs are less susceptible to complement-mediated killing than cells growing in monolayer cultures, even after neutralization of protectin (CD59), the main inhibitor of complement lysis. Cells in suspension and cells growing in TMSs showed a similar expression of membrane co-factor protein (MCP, CD46) and CD59. Decay-accelerating factor (DAF, CD55) was not detected on the surface of cells in suspension, but appeared focally on the outermost cell layers of the TMSs. Complement-activating antibodies bound to all PA-1 cells in suspension but only to the most peripherally located cells in TMSs, even though the target antigens were similarly expressed in the two systems. Antibody-induced complement activation on PA-1 cells in suspension led to C3 and C5b-9 deposition on most cells, while C3 and C5b-9 were only found on the outermost layers of the TMSs. The increased complement resistance of tumour cells growing in three-dimensional spheroids is partly because of an insufficient penetration of antibodies and complement into the TMSs. TMSs are a useful model for the development of more efficient ways to kill malignant cells in micrometastases with monoclonal antibodies and complement.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9155042      PMCID: PMC2228228          DOI: 10.1038/bjc.1997.213

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  41 in total

1.  Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 125I-antibody therapy efficacy in multicell spheroids.

Authors:  V K Langmuir; H L Mendonca; D V Woo
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

2.  Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.

Authors:  Y Reiter; A Ciobotariu; Z Fishelson
Journal:  Eur J Immunol       Date:  1992-05       Impact factor: 5.532

3.  Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels.

Authors:  Y Sugita; Y Nakano; M Tomita
Journal:  J Biochem       Date:  1988-10       Impact factor: 3.387

Review 4.  Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects.

Authors:  B P Morgan
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

5.  Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

Authors:  S Meri; B P Morgan; A Davies; R H Daniels; M G Olavesen; H Waldmann; P J Lachmann
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

6.  The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.

Authors:  S A Rollins; P J Sims
Journal:  J Immunol       Date:  1990-05-01       Impact factor: 5.422

7.  Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer.

Authors:  G E Goodman; I Hellström; L Brodzinsky; C Nicaise; B Kulander; D Hummel; K E Hellström
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

8.  New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.

Authors:  A Fletcher; J A Bryant; B Gardner; P A Judson; F A Spring; S F Parsons; G Mallinson; D J Anstee
Journal:  Immunology       Date:  1992-03       Impact factor: 7.397

9.  Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).

Authors:  C H Holmes; K L Simpson; H Okada; N Okada; S D Wainwright; D F Purcell; J M Houlihan
Journal:  Eur J Immunol       Date:  1992-06       Impact factor: 5.532

10.  Cell and environment interactions in tumor microregions: the multicell spheroid model.

Authors:  R M Sutherland
Journal:  Science       Date:  1988-04-08       Impact factor: 47.728

View more
  6 in total

1.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

2.  Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs.

Authors:  Ekaterina Schreiber-Brynzak; Erik Klapproth; Christine Unger; Irene Lichtscheidl-Schultz; Simone Göschl; Sarah Schweighofer; Robert Trondl; Helmut Dolznig; Michael A Jakupec; Bernhard K Keppler
Journal:  Invest New Drugs       Date:  2015-06-21       Impact factor: 3.850

3.  In vitro and in vivo antitumor effects of the VO-chrysin complex on a new three-dimensional osteosarcoma spheroids model and a xenograft tumor in mice.

Authors:  Ignacio E León; Juan F Cadavid-Vargas; Agustina Resasco; Fabricio Maschi; Miguel A Ayala; Cecilia Carbone; Susana B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2016-10-01       Impact factor: 3.358

4.  Ascitic complement system in ovarian cancer.

Authors:  L Bjørge; J Hakulinen; O K Vintermyr; H Jarva; T S Jensen; O E Iversen; S Meri
Journal:  Br J Cancer       Date:  2005-03-14       Impact factor: 7.640

5.  Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

Authors:  S Junnikkala; J Hakulinen; H Jarva; T Manuelian; L Bjørge; R Bützow; P F Zipfel; S Meri
Journal:  Br J Cancer       Date:  2002-11-04       Impact factor: 7.640

6.  Strategies to increase drug penetration in solid tumors.

Authors:  Il-Kyu Choi; Robert Strauss; Maximilian Richter; Chae-Ok Yun; André Lieber
Journal:  Front Oncol       Date:  2013-07-26       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.